FDA approves first dual-use anxiety drug for dogs

FDA has approved Tessie, an oral tasipimidine solution from Orion Corporation, as the first drug labeled to treat both noise aversion and separation anxiety in dogs. The approval was announced May 6, 2026, by the FDA’s Center for Veterinary Medicine, which said the product is indicated for two common fear-based behavioral disorders that have previously had separate drug options, but not a single FDA-approved product covering both. In the agency’s approval summary, Tessie was supported by one field study in 160 client-owned dogs for noise aversion and an 8-week field study in 224 client-owned dogs for separation anxiety. It’s a prescription product, dosed orally at 30 mcg/kg, with a recommendation to give it 1 hour before the triggering event or departure, and to avoid giving it with food because absorption may be delayed. (fda.gov)

Why it matters: For veterinary professionals, the approval gives clinicians a new labeled option for dogs with overlapping fear-based presentations, a common real-world challenge in behavior cases. The FDA says tasipimidine is an alpha-2 adrenoceptor agonist, and the approval documents note common adverse reactions including vomiting, lethargy, and, in the separation-anxiety study, diarrhea. dvm360’s coverage and AAHA’s follow-up both emphasize that medication should not be used in isolation, aligning with longstanding behavior guidance that pharmacologic support works best alongside behavior modification and environmental management. (dvm360.com)

What to watch: Watch for uptake in general practice, post-approval safety experience around sedation and dosing at home, and whether Orion pursues broader commercialization or additional market approvals. (animaldrugsatfda.fda.gov)